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Abstract
Background: Following a recent major review of cervical screening, from 2017 Australia will transition from two-yearly
cytology-based screening to five-yearly primary HPV screening, with partial genotyping and direct referral for HPV 16/18
and LBC triage for other oncogenic types. Switching to a longer screening interval will result in transitional fluctuations for
volumes of tests before a 'steady state' is reached for the new test volumes. This study aimed to quantify the impact of
this transition on year-to-year volumes of screening and follow-up tests and procedures.
Methods: Number of women screened and test volumes from 2015 to 2032 were estimated via a detailed simulation
model which explicitly modelled varying screening and HPV vaccination exposure in individual birth cohorts, and fully
incorporated how a relatively rapid screening program switch in 2017 would affect both women attending for routine
screening and those in surveillance following an abnormality.
Results: Numbers of women screened and HPV tests are predicted to fluctuate in the first screening rounds as a
result of the transition to a longer screening interval (mean women screened and HPV tests 1.4 million in the first 5-
year period, year-to-year fluctuation > +/−50 %; mean 1.5 million women/HPV tests in third 5-year period, fluctuation
approximately +/−25 %). The extent to which this fluctuation was predicted to carry through to secondary tests/
procedures was less (fluctuations of +25 %/-31 % in first 5-year period; decreasing to +8 %/-10 % by third round). HPV
vaccination is predicted to counteract increases in high grade cytology results, colposcopies and precancer treatments
which would otherwise occur due to population increases. Precancer treatments are predicted to drop below 2015
levels within the first few years of program switchover. Mean colposcopy volumes are predicted to be similar to 2015
levels by the third round of HPV-based screening, and also be 25–40 % lower than would have occurred in the
absence of HPV vaccination.
Conclusions: While numbers of women attending for screening and HPV tests are anticipated to initially fluctuate as a
result of the transition to a longer recommended interval, there is expected to be less fluctuation in follow-up tests and
procedures; however these will still have a significant impact on operational aspects of the screening program. Detailed
modelling of the switchover process gave important insights into how volumes would be affected.
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Background
As a result of a recent review of the National Cervical
Screening Program (NCSP) in Australia (known as
“Renewal”), major changes are planned [1]. Broadly,
these changes involve a switch from a recommendation
of two-yearly screening with conventional cytology be-
tween the ages of 18–69 years, to five-yearly screening
between the ages of 25–74 years using primary testing
for human papillomavirus (HPV) with partial genotyping
for HPV 16/18, and liquid-based cytology (LBC) triage
for women who test positive for oncogenic HPV types
other than 16/18 [1]. In addition, the NCSP will change
to an active call-recall system – inviting women to be
screened when they turn 25 and recalling them when
they are due to re-attend - rather than a reminder sys-
tem, where letters are only sent to women who are
3 months overdue for their next recommended test. The
organisation of the cervical screening register will also
change from eight jurisdiction-specific Pap test registers
(which only include women who have been screened at
least once within that jurisdiction), to a single national
cancer screening register, populated with whole-of-
population data. These changes are expected to be im-
plemented from May 2017, and the use of conventional
cytology for cervical screening is expected to be phased
out within 6–12 months via removal of the reimburse-
ment for this test [1]. Therefore, a relatively rapid
switchover from the current practice of two-yearly
cytology-based screening to primary HPV-based screen-
ing is planned to occur, starting in 2017.
As part of the Renewal process, extensive evidence-
based modelling of potential screening strategies was
undertaken and resource utilisation estimates were made
[2]. Resource utilisation estimates included the annual
numbers of HPV tests, cytology tests, colposcopies, and
women treated for precancerous lesions. However, these
previous estimates from the model represented post-
transitional ‘steady-state’ estimates. In the period after
implementation, the program will be switched from a 2-
year interval to a 5-year interval across all target ages
within a comparatively short period, since women pre-
dominantly re-attend in a 2- to 3-year timeframe after
their most recent screening test. As a result, there will
potentially be fluctuations in women attending and re-
source utilisation due to the change in the recom-
mended interval, and this would have implications for
workforce and resource planning around the transition.
The aim of the current study was to estimate the year-
by-year volumes immediately before and for the first
15 years after the introduction of the renewed program
(2015–2032; approximately three screening rounds) of:
number of women screened, HPV tests, LBC tests, col-
poscopies and precancer treatments following the imple-
mentation of the Renewed program, taking into account
the different ways women transition into the new pro-
gram and the impact of HPV vaccination. This was done
in two ways, in order to compare the results from a sim-
pler more intuitive versus a more detailed modelled ap-
proach. An additional comparison was made with what
volumes would have been expected in the absence of a
change to the screening program and/or HPV vaccin-
ation, in order to clarify which changes were due to
demographic change, which were due to the screening
program change and which were due to the impact of
HPV vaccination, since by 2017 women aged up to
36 years will have been offered vaccination through a na-
tional publicly-funded vaccination program.
Methods
As part of the original Renewal evaluation of primary
HPV screening, we developed a detailed model of cer-
vical screening according to the now recommended
changes (“proposed pathway”; see Fig. 1), which we used
in a comparison with current screening practice [2].
Management pathways for screen-positive women were
based on a pre-specified protocol [3], existing guidelines
[4], and expert advice from the Renewal Steering Com-
mittee [2]. Briefly, women who test negative for onco-
genic HPV are recommended to return in 5 years;
women who test positive for oncogenic HPV all have re-
flex LBC. Women who test positive for HPV 16/18 are
referred for colposcopy, and the results of their reflex
LBC test are used to inform colposcopy; women who
test positive only for other (non-16/18) oncogenic HPV
types are triaged to either immediate colposcopy or a re-
peat HPV test in 12 months, based on the result of their
reflex LBC test. This screening model was based on a
model platform developed over many years, which has
been extensively validated and widely used for HPV vac-
cination and cervical screening policy evaluations for
Australia, New Zealand, England and China [5–15]. The
platform consists of multiple elements including models
of sexual behaviour, HPV transmission, natural history of
HPV infection, HPV vaccination, screening behaviour, man-
agement of screen-detected abnormalities including treat-
ment of precancerous lesions, and cervical cancer
treatment and survival (see Additional file 1). These ele-
ments have previously been described in detail [2].
The model incorporates detailed rescreening behav-
iour, informed by a previous analysis of data from the
Victorian Cervical Cytology Registry (VCCR) [11], which
records all cytology and histology tests undertaken in
the state of Victoria (approximately a quarter of the
Australian population) unless women have opted off the
VCCR. This approach was able to account for some de-
gree of early and late rescreening by women, and vari-
ation by age (see Additional file 1) [2]. Since the
transitional recommendations were not yet available at
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the time of this analysis, for this evaluation we assumed
that from 2017, several changes would occur in screen-
ing behaviour, consistent with the Renewal recommen-
dations and the draft reimbursement schedule for
cervical screening tests (which restricts testing to
women aged 25–74 years and no sooner than 57 months
after a negative HPV screening test, or for management
of a previous abnormality) [1], since these recommenda-
tions and reimbursement restrictions are intended to
alter screening behaviour. For women aged 25 or less,
assumed changes include that from 2017 women aged
less than 25 years would no longer initiate screening but
that women aged less than 25 years who had initiated
screening prior to 2017 may re-attend (for example to
follow-up a recent abnormality; the simple estimates
additionally considered that re-attendance by women
aged less than 25 would be only half what it was prior to
2017); that all women would receive an invitation to at-
tend for cervical screening in the year they were aged
25 years, unless they had attended for screening in the
previous year; and that uptake would be fast (74 % at
age 25; 83 % by age 29; consistent with current initiation
patterns before age 30) [2]. We assumed that from 2017
on, all women attending for screening would be
screened using HPV as the primary test with follow-up
according to the proposed pathway. It was assumed that
no women who were screen-negative would re-attend in
the first 3 years after a screening visit (based on reim-
bursement restricting routine testing to within 57 months
of a negative HPV test), however some early re-
screening was assumed to occur in the fourth year after
a negative HPV test (see Additional file 1) [2]. As there
were no direct local data on screening behaviour in the
context of an active call-and-recall (rather than
reminder-only) system using a whole-of-population
register, we used registry data from England, where a
call-and-recall system was in place, to inform estimated
patterns around early versus on-time versus late rescre-
ening, using previously described methods [2, 11]. It was
assumed, however, that changing the recommended
interval would not alter screening behaviour in very
underscreened women, so in order to take between-
country differences into account, the re-attendance rates
for England were modified so that the modelled propor-
tion of women not screened for at least 7 years was con-
sistent with that observed in Australia under current
practice [2].
Table 1 summarises the scenarios examined. In the main
analysis, we assumed the present reminder system would
continue over the transition period; that is, that reminders to
attend would only be sent to women who are 3 months
overdue for their next recommended test (generally 27
months after a negative cytology result) (‘gradual change’). In
this case, women already in the program would not be ac-
tively recalled for screening either before or around the time
that they are due until after they have had their first primary
HPV screen. In an alternative scenario, we examined the im-
pact of an additional active ‘recall’ in 2018 as part of the tran-
sition, where all women aged 26–69 years who had
previously been screened but were not screened in 2017
would be sent an invitation to attend in 2018 (ie 24 months
or more after their most recent screening test). The response
rate to this invitation was assumed to be relatively high; spe-
cifically, this was done by assuming that the cumulative pro-
portion of women last screened in 2015 or 2016 who were
re-screened by the end of 2018 was at least as high as it
Fig. 1 Proposed cervical screening algorithm in Australia from May 2017. Detailed clinical management guidelines are currently being developed; this
algorithm is based on that recommended by the Medical Services Advisory Committee [1]. Reflex LBC is performed in all women who test positive for
oncogenic HPV. For women who test positive to HPV 16/18, the LBC result does not affect the referral decision, but is used to inform colposcopy
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would be in response to the recall invitation sent 5 years
after an HPV test (see Additional file 1). In practice, this
meant that approximately 77–90 % of women aged 26–69
years who were screened in 2015 or 2016 had re-attended
by the end of 2018 (range represents variation by age);
and on average 90 % or more of women who
were screened at least once between 2008 and 2014 had
re-attended by the end of 2018. With respect to assump-
tions around initiating screening, in both the active recall
and the gradual change scenarios, the same assumptions
were made for inviting women at age 25.
Estimates of the number of women screened and test
volumes
We used two methods to estimate the future number of
women screened and test volumes. A simpler hybrid ap-
proach estimated the future number of women screened
from previously observed data on attendance and pat-
terns of re-attendance from the VCCR analysis. Model
predictions of age-specific resource use per woman
screened were then used to translate the expected num-
ber of women screened into expected test and procedure
volumes. The detailed method involved modelling indi-
vidual birth cohorts’ differing exposure to each of the
current and the proposed screening program over their
lives. The details of each method are described below.
Both methods take into account HPV vaccination using
similar assumptions around vaccine uptake, so this is de-
scribed in a separate section. Both methods used Australian
Bureau of Statistics (ABS) estimates for the projected popu-
lation by age (Series B) to estimate the number of women
invited at age 25 [16].
Simpler (hybrid) method
The expected number of women screened was estimated
starting from age-specific counts of the number of
women screened in each calendar year between 2003
and 2012 (the most recent year for which published data
Table 1 Summary of scenarios examined
Scenario name Model Vaccination? Description
Gradual change (simple method) Simple No Assumes a gradual change to the new program in 2017 (no recall invitations
sent to women aged >25 until after their first HPV screening test; current
system where reminders are only sent to women who are 3 months overdue
for their next recommended test remains in place). Re-attendance is assumed
to be equivalent to that observed under the current reminder-based system.
Active recall 2018 (simple method) Simple No Assumes an active recall invitation is sent in 2018 to all women due for
screening who did not attend in 2017 ie sent two years or more after their
most recent cytology screening test. Re-attendance following this invitation is
assumed to be at least as high as that under a call-recall invitation system after
a routine HPV test.
Gradual change (detailed method) Detailed No Assumes a gradual change to the new program in 2017 (no recall invitations
sent to women aged >25 until after their first HPV screening test; current
system where reminders are only sent to women who are 3 months overdue
for their next recommended test remains in place). Re-attendance is assumed
to be equivalent to that observed under the current reminder-based system.
Simple method – approximate vaccine
effect
Simple Yes Simpler estimates assuming a gradual change to the new program in 2017 and
approximating the effect of HPV vaccination: vaccine effect is applied to
women born in 1981 or later (ie aged 26 or less for at least the first six months
of the catch-up HPV vaccination program)
Simple method – no vaccine effect Simple No Simpler estimates assuming a gradual change to the new program in 2017 but
no effect of HPV vaccination (what would have been observed under the new
program in the absence of HPV vaccination)
Detailed method with vaccination/Program
change in 2017 with vaccination
Detailed Yes Detailed estimates assuming a gradual change to the new program in 2017
and taking into account the effect of HPV vaccination over time (best and most
detailed estimates for likely future resource use)
Detailed method – no vaccine effect/
Program change in 2017 – no vaccine
effect
Detailed No Detailed estimates assuming a gradual change to the new program in 2017
but no effect of HPV vaccination (what would have been observed under the
new program in the absence of HPV vaccination): this counterfactual allows
examination of the effect of the screening program change and demographic
change only.
Current practice with vaccination Detailed Yes Detailed estimates of resource use in the absence of any change to the current
program (see Additional file 1: Figure S2) but which take into account the
effect of HPV vaccination: this counterfactual allows examination of the effect
of HPV vaccination and demographic change only.
Current practice – no vaccine effect Detailed No Detailed estimates of resource use in the absence of any change to the current
program and in the absence of HPV vaccination: this counterfactual allows
examination of the effect of demographic change only.
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were available) [17, 18]. From 2013 on, the number of
women attending was estimated based on the same ana-
lysis of VCCR data as is incorporated into the model. This
analysis described the interval-specific probability that a
woman will return after a routine negative screening test
(routine recall) for intervals of 1 to 10 years. A proportion
of women were assumed to return at 12 months due to a
positive screening test where recommended follow-up was
12 months rather than colposcopy referral based on pre-
liminary clinical implementation data.
In order to estimate test/procedure volumes, the simpler
method derived an estimated rate of tests/procedures per
woman screened (“resource-use rates”) from the steady-
state estimates from the detailed screening model. Age-
specific resource-use rates were then applied to age-specific
estimates of the number of women screened in a given year,
and totals for each year obtained by summing across all
ages. Age-specific resource-use rates were able to take into
account differences both in the underlying risk of disease,
and the probability that a woman will attend for screening;
and were additionally able to take into account the impact
of HPV vaccination in younger birth cohorts. Additional
details are provided in Additional file 1.
Detailed method
To obtain detailed estimates that accounted for women’s
different screening histories at the time of program transi-
tion, the cohort-based screening model was configured to
run separately for each birth cohort, and so that in all cases
women were screened according to the current pathway
prior to 2017, then according to the proposed program
from 2017. HPV incidence for each birth cohort was de-
rived from a dynamic transmission model which took into
account both direct and indirect protection from HPV vac-
cination. Model predictions of the age-specific proportion
of women screened and resource-use rates were scaled for
each cohort according to the estimated resident population
of Australia by age and calendar year to obtain cross-
sectional outcomes [16].
Accounting for the impact of HPV vaccination
The National HPV Vaccination Program in Australia
commenced in 2007 for females, and included catch-up
vaccination for females aged 12–26 years until the end of
2009 [19, 20]. Since 2010, girls aged 12–13 have been of-
fered vaccination, with the addition of boys from 2013, in-
cluding catch-up of boys aged 14–15 over 2013 and 2014.
Both the simpler and detailed estimates incorporated the
effect of HPV vaccination with uptake for females across
different ages as observed in the current vaccination pro-
gram [2]. National uptake data in males were not yet avail-
able so we assumed equivalent coverage in males offered
vaccination from 2013 as achieved in females offered
vaccination at the same age, based on initial state-based
reports of similar uptake [21].
The original estimates from Renewal presented test vol-
umes for two types of modelled cohort – one in the ab-
sence of a vaccination program, and the other where the
women had been offered vaccination at the age of 12 years
[2]. The simpler estimates accounted for the impact of
HPV vaccination in the current year-by-year estimates
using a hybrid approach, where there is assumed to be a
vaccine effect in women born in 1981 or later (aged 26 or
less throughout 2007), but no impact of vaccination in
women born prior to 1981 (aged 27 years or older in
2007) (see Additional file 1). For the detailed estimates,
birth cohorts were modelled individually and so directly
incorporated the relevant vaccine uptake, as well as in-
corporating any indirect protection effects.
Results
Figure 2 shows the estimated number of women screened
in each year from 2015 to 2032, either in the context of a
more gradual change from current practice to the pro-
posed pathway (reminders only are sent out prior to
women’s first HPV test; active recall commences after a
woman’s first HPV test), or alternatively a rapid transition
(active recall in 2018, assuming a similar response rate to
that for an active recall 5 years after a woman’s first HPV
test). The estimated number of women screened was
broadly similar for both the simpler and detailed methods.
An active recall in 2018 is likely to substantially increase
the number of women screened in 2018, and every 5 years
later, compared to what would be expected with a gradual
change. This was primarily due to the active call in 2018
creating a shift in attendance by women most recently
screened in 2016 to predominantly re-attend 2 years later
in 2018, rather attending over 2018–2019, which would
have been the expected pattern based on observed screen-
ing behaviour in the context of reminders only. A sensitiv-
ity analysis was performed on the assumption that re-
attendance for screening in women aged less than 25 years
would halve after 2017 compared to what it would have
been, in light of them no longer being in the target age
range for screening. Re-attendance by women aged less
than 25 years was scaled by 0.1 (ie 90 % reduction in
women re-attending compared to current patterns) and
0.9 (ie 10 % reduction in women re-attending compared
to current patterns); this had no appreciable impact on
the number of women screened (data not shown).
Figure 3 compares estimates from the simple versus de-
tailed methods assuming in both cases that there is a grad-
ual change to the proposed pathway (reminders only prior
to first HPV test; no active recall in 2018), and indicates
the variation in expected volumes which is due to the im-
pact of HPV vaccination and for each method. Volumes
are generally predicted to fluctuate over a 5-year cycle, as
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a consequence of the predicted fluctuations in the number
of women screened. These fluctuations are predicted to
decrease in magnitude with each screening round. As the
primary test, the number of HPV tests was estimated to
be very similar regardless of whether vaccination was
taken into account or not, and the estimated volumes
were similar from the simple and detailed method (Fig. 3).
When vaccination is taken into account, and based on the
detailed modelling, the number of HPV tests is likely to
vary from ~670,000 to ~2.28 million within the first five
years of the renewed program, representing a fluctuation
of +59 %/-53 % compared to its mean value in the 5-year
period (~1.4 million) (Table 2). By the third round (2027–
2031), the fluctuation in HPV test volumes is predicted to
be less, from ~1.1 million to 1.9 million, but this is still
relatively large in relation to the mean value (+24 %/-25 %
of the mean value of 1.5 million).
The simple and detailed methods differed, however, in
their estimates for volumes of follow-up tests and proce-
dures. The simpler method predicted a much greater
fluctuation in volumes (commensurate with the pattern
for HPV tests) than the detailed method (Fig. 3). In both
cases HPV vaccination was predicted to reduce the over-
all volumes (but not necessarily the magnitude of the
fluctuations). When vaccination is taken into account,
and based on the detailed modelling, the number of cy-
tology tests, high grade cytology results, colposcopies
and precancer treatments fluctuated by +8/-10 % or less
by the third 5-year cycle.
When compared to the expected change in volumes in
the absence of a change to the screening program
(where changes are due to population change or HPV
vaccination only), it could be seen that with or without a
screening program change, HPV vaccination is predicted
to counteract increases in high grade cytology results,
colposcopies and precancer treatments which would
otherwise be anticipated due to population increases
(Fig. 4). Volumes of high grade cytology and precancer
treatments are predicted to drop below 2015 levels
within the first few years of program switchover, how-
ever this effect was driven by the screening program
change, and would have occurred even in the absence of
HPV vaccination (Fig. 4, Table 3). By the third round of
HPV-based screening, mean colposcopy volumes are
predicted to be similar to both current levels and to
those which would have occurred in the absence of
screening program change, and also be 20–35 % lower
than would have occurred under either screening pro-
gram in the absence of HPV vaccination. Volumes of
precancer treatments were additionally considered in
terms of the number which would be expected to occur
in women aged less than 45 years (as precancer treat-
ments are potentially linked to adverse obstetric out-
comes [22–24] and 99.7 % of births in Australia occur in
women aged less than 45 years [25]). As for precancer
treatments in all ages, an initial increase in precancer
treatments was predicted to occur due to the use of a
more sensitive primary test; however from around 2020
onwards, the volume of precancer treatments in women
aged less than 45 years is predicted to be lower than it
would have been in the absence of program change
(Fig. 4d).
We additionally compared the predicted volumes dur-
ing the third round of screening under the renewed pro-
gram (2027-2031) with those predicted by the model at
steady state, consistent with the approach used for previ-
ously published findings [2], but updated compared to
previous estimates to reflect the average underlying
population in 2027-2031 (Additional file 1: Table S1).
The mean predicted volumes during 2027-2031 were
Fig. 2 Estimated number of women attending for cervical screening, by year
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Fig. 3 Estimated volumes of a HPV tests; b cytology tests; c high grade cytology results; d colposcopies; and e precancer treatments under the
new proposed pathway with and without the impact of HPV vaccination: comparison of predictions from simple versus detailed method.
High grade cytology results: those with a result of HSIL or ASC-H (Atypical squamous cells, possible high grade lesion) in The Bethesda System
2001; this is equivalent to possible HSIL in the Australian Modified Bethesda System 2004. High grade cytology results do not include those
performed as a reflex test for women testing positive for HPV 16/18 at the primary test, nor those resulting from samples collected at colposcopy.
Approximate vaccine impact = assumes rates as per cohorts offered vaccination at age 12 for all women born in 1981 or later (ie aged 26 or less
throughout 2007), and rates as per unvaccinated cohorts for women born before 1981. No vaccine impact = estimates in the absence of HPV
vaccination. Detailed method with vaccination = incorporates the effect of HPV vaccination (including indirect protection of unvaccinated
individuals) based on observed uptake in individual birth cohorts
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consistent with the steady state estimates in the absence
of HPV vaccination, and in the context of HPV vaccin-
ation for number of women screened, and HPV tests
(where the impact of vaccination on predicted volumes
was relatively small). In 2027-2031, the number of cy-
tology tests, high grade cytology results, colposcopies
and precancer treatments was approaching, but had not
yet reduced to, those predicted by the steady state
Table 2 Five-year averages and fluctuations in predicted volume estimates for HPV tests, cytology tests, high grade (ASC-H/HSIL)
cytology results, colposcopies, and treatments for precancerous lesions, 2015–2031 (detailed method)
Including vaccination effect No vaccine effect
2015 2017–2021 2022–2026 2027–2031 2015 2017–2021 2022–2026 2027–2031
Women screened
Mean 2,297,161 1,412,933 1,442,095 1,498,228 2,300,662 1,430,693 1,468,363 1,534,421
Min 655,625 900,795 1,128,045 683,095 942,133 1,178,039
Max 2,256,515 1,977,963 1,858,245 2,262,166 1,992,569 1,882,566
% fluctuation (−) −53.6 % −37.5 % −24.7 % −52.3 % −35.8 % −23.2 %
(+) 59.7 % 37.2 % 24.0 % 58.1 % 35.7 % 22.7 %
HPV tests
Mean 54,380 1,413,004 1,442,838 1,497,588 55,857 1,430,105 1,468,317 1,532,790
Min 658,946 900,189 1,127,018 685,697 940,671 1,175,952
Max 2,248,033 1,980,721 1,857,781 2,253,235 1,994,633 1,881,146
% fluctuation (−) −53.4 % −37.6 % −24.7 % −52.1 % −35.9 % −23.3 %
(+) 59.1 % 37.3 % 24.1 % 57.6 % 35.8 % 22.7 %
Cytology
Mean 2,409,923 370,206 323,456 313,008 2,418,505 412,178 391,910 408,425
Min 272,018 279,994 287,389 320,588 359,966 392,498
Max 462,288 357,152 333,685 490,507 419,585 424,015
% fluctuation (−) −26.5 % −13.4 % −8.2 % −22.2 % −8.2 % −3.9 %
(+) 24.9 % 10.4 % 6.6 % 19.0 % 7.1 % 3.8 %
ASC-H/HSIL cytology
Mean 31,002 16,607 14,462 14,100 33,532 19,504 18,415 19,307
Min 11,869 12,885 13,187 14,910 17,358 18,768
Max 20,281 15,763 14,831 22,888 19,436 19,837
% fluctuation (−) −28.5 % −10.9 % −6.5 % −23.6 % −5.7 % −2.8 %
(+) 22.1 % 9.0 % 5.2 % 17.4 % 5.5 % 2.7 %
Colposcopies
Mean 77,508 95,367 82,677 78,421 83,234 117,901 116,479 121,557
Min 65,633 69,454 70,464 86,276 105,079 115,722
Max 117,173 94,166 85,045 142,970 128,322 127,757
% fluctuation (−) −31.2 % −16.0 % −10.1 % −26.8 % −9.8 % −4.8 %
(+) 22.9 % 13.9 % 8.4 % 21.3 % 10.2 % 5.1 %
Treatments
Mean 20,011 17,593 15,572 14,694 21,984 21,745 22,375 23,395
Min 12,680 13,604 13,507 16,945 21,002 22,763
Max 21,104 17,176 15,597 25,345 23,858 24,091
% fluctuation (−) −27.9 % −12.6 % −8.1 % −22.1 % −6.1 % −2.7 %
(+) 20.0 % 10.3 % 6.1 % 16.6 % 6.6 % 3.0 %
ASC-H atypical squamous cells, possible high grade lesion in The Bethesda System 2001; ASC-H is equivalent to possible HSIL in the Australian Modified Bethesda
System 2004. High grade cytology results do not include those performed as a reflex test for women testing positive for HPV 16/18 at the primary test, nor those
resulting from samples collected at colposcopy. Treatments are for cervical intraepithelial neoplasia (does not include cancer treatments)
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Fig. 4 (See legend on next page.)
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estimates in the context of HPV vaccination. This is
likely because cohorts offered vaccination did not yet
make up enough of the screening population for these
volumes to have reached steady state.
Discussion
These findings indicate that as Australia transitions from a
2-year to a 5-year screening interval within a relatively short
timeframe, the number of women screened each year, and
consequently volumes of tests and follow-up procedures,
will fluctuate. These fluctuations will likely pose resourcing
and workforce challenges which need to be accounted for
in planning. The requirement to scale up again after years
where volumes have been lower is likely to be particularly
challenging. An initial transitional active recall in 2018
would exacerbate this fluctuation effect compared to main-
taining the reminder-based system until after women have
had their first primary HPV test, primarily due to bringing
forward re-attendance by women most recently screened in
2016 to predominantly occur 2 years later in 2018, rather
spread over 2018–2019, as would have been expected in
the context of reminders only. Focussing efforts on reach-
ing unscreened or underscreened women in the years
where volumes are otherwise anticipated to be lower may
potentially reduce fluctuations, however this was not expli-
citly examined here.
Table 3 Mean volumes of women screened, HPV tests, cytology tests, high grade or worse (ASC-H/HSIL) cytology results,
colposcopies, and treatments for precancerous lesions (2015–2031) under different screening and vaccination assumptions (detailed
method)



































2,297,161 2,429,487 1,412,933 −41.8 % 2,585,465 1,442,095 −44.2 % 2,737,383 1,498,228 −45.3 %
No
vaccination
2,300,662 2,436,693 1,430,693 −41.3 % 2,595,623 1,468,363 −43.4 % 2,750,112 1,534,421 −44.2 %
HPV tests With
vaccinationa
54,380 53,273 1,413,004 2552.4 % 50,653 1,442,838 2748.5 % 47,873 1,497,588 3028.2 %
No
vaccination
55,857 59,390 1,430,105 2308.0 % 63,263 1,468,317 2221.0 % 66,699 1,532,790 2198.1 %
Cytology With
vaccinationa
2,409,923 2,544,000 370,206 −85.4 % 2,702,457 323,456 −88.0 % 2,857,249 313,008 −89.0 %
No
vaccination





31,002 30,661 16,607 −45.8 % 30,538 14,462 −52.6 % 30,671 14,100 −54.0 %
No
vaccination
33,532 35,399 19,504 −44.9 % 37,391 18,415 −50.7 % 39,406 19,307 −51.0 %
Colposcopies With
vaccinationa
77,508 76,462 95,367 24.7 % 75,740 82,677 9.2 % 75,566 78,421 3.8 %
No
vaccination
83,234 88,087 117,901 33.8 % 93,199 116,479 25.0 % 98,136 121,557 23.9 %
Treatments With
vaccinationa
20,011 19,214 17,593 −8.4 % 18,432 15,572 −15.5 % 17,895 14,694 −17.9 %
No
vaccination
21,984 23,254 21,745 −6.5 % 24,572 22,375 −8.9 % 25,871 23,395 −9.6 %
aHPV vaccination as has been implemented in Australia; ie females from 2007; males from 2013; catch-up vaccination for females aged 12–26 in 2007–2009 and males
aged 14–15 in 2013–2014. ASC-H: Atypical squamous cells, possible high grade lesion in The Bethesda System 2001; ASC-H is equivalent to possible HSIL in the
Australian Modified Bethesda System 2004. High grade cytology results do not include those performed as a reflex test for women testing positive for HPV 16/18 at the
primary test, nor those resulting from samples collected at colposcopy. Treatments are for cervical intraepithelial neoplasia (does not include cancer treatments)
(See figure on previous page.)
Fig. 4 Estimated volumes of a high grade cytology results; b colposcopies; c precancer treatments; and d precancer treatments in women aged
less than 45 years by year with and without the impact of HPV vaccination: comparison of current program with proposed pathway. High grade
cytology results: those with a result of HSIL or ASC-H (Atypical squamous cells, possible high grade lesion) in The Bethesda System 2001; ASC-H is
equivalent to possible HSIL in the Australian Modified Bethesda System 2004. High grade cytology results do not include those performed as a
reflex test for women testing positive for HPV 16/18 at the primary test, nor those resulting from samples collected at colposcopy
Smith et al. BMC Health Services Research  (2016) 16:147 Page 10 of 14
While this study examined a specific situation in
Australia, these findings would also be relevant to other
settings planning to shift to a longer screening interval.
This is likely to occur in the future, as several settings are
actively considering or piloting a change from cytology-
based to HPV-based cervical screening at longer intervals
[26]. To our knowledge, this is the first study which has
considered in detail test volumes and implications over a
transition period from cytology-based to HPV-based pri-
mary screening at a longer interval.
This study was also able to separate out the effect of
three major changes which will be occurring in the com-
ing years, all of which will impact volumes of tests in the
screening program – the impact of HPV vaccination, the
impact of a restructure of the cervical screening pro-
gram, and the ongoing impact of population growth. We
found that even in the absence of any screening program
change increases would be expected in case numbers for
high grade cytology results, colposcopy referrals and
precancer treatment as a result of population growth,
but that over the next 10–15 years HPV vaccination
would tend to counteract this increase. A similar pattern
was also observed in the context of a screening program
change from 2017, but with an overlay of fluctuating
volumes due to the extension of the screening interval.
However it is predicted that apart from an initial in-
crease (in part due to a more sensitive test), colposcopy
volumes would essentially drop below volumes which
would have been expected in the absence of screening
change or vaccination from around 2020, and that pre-
cancer treatments would drop below the levels expected
in the absence of program change even after taking vac-
cine impact into account after around 2019.
The strengths of this study were that population-based
data were used to estimate attendance for screening dur-
ing the transition period, and also that it used a robust
and well-calibrated model of HPV natural history, vac-
cination and cervical screening [2]. This model was spe-
cifically adapted during the review of the NCSP to
include detailed clinical management pathways for the
current and proposed new program, informed by an ex-
pert advisory committee (the Renewal Steering Commit-
tee) [2]. Other model assumptions were also reviewed by
this multidisciplinary local expert advisory committee.
The model was also informed by a concurrent review of
the literature on screening test characteristics [27], and
because it incorporated dynamic modelling of HPV
transmission, was able to take into account the likely im-
pact of HPV vaccination on volumes over this period.
This was an important consideration, as the impact of
HPV vaccination on estimated volumes is fairly
substantial.
Our analysis also has several limitations. Firstly, for
simplicity, these estimates assumed that the program
would switch over at the beginning of 2017, and not
from May 2017, as is currently planned. As a result, the
timing of the fluctuations predicted here is potentially
around six months earlier than would be observed – for
example, the patterns or volumes shown here for a cal-
endar year might in practice correspond more closely to
a July-June year. The volumes are also presented at the
level of a whole year, and were not able to examine fluc-
tuations within smaller intervals. Secondly, the modelled
screening behaviour used in both the simpler and de-
tailed methods also does not take into account changes
in screening behaviour since the time period of the
screening register analysis, for example falling participa-
tion in younger women, particularly those who have
been vaccinated [28]. The estimates were also unable to
take into account any changes in screening behaviour
which may occur in the lead up to the transition, for ex-
ample if some women delay their routine screening visit
for longer than usual in order to obtain an HPV test. It
also does not take into account the potential impact of
specific measures included in the new program to target
unscreened and underscreened women, in particular the
offer of self-collection facilitated by a health professional,
because there were no directly comparable data to in-
form what the response to this offer will be. Thirdly,
case numbers for high grade cytology results are under-
estimated to an extent, as they do not include those tests
which are performed on women testing positive for HPV
16/18 at the primary test (as this cytology result is used
to inform colposcopy, but does not alter the colposcopy
referral decision), nor high grade cytology resulting from
samples collected at colposcopy. Fourthly, HPV vaccine
impact may have been underestimated, and if so this
would potentially affect the estimated volumes of cy-
tology (including high grade cytology), colposcopies and
precancer treatments. Vaccine impact may have been
underestimated by modelling uptake based on three-
dose uptake reported to the national vaccination register.
Notifications to the register from primary care providers
was voluntary, however, and in females vaccinated as
young women, survey data suggest that doses delivered
through the primary care catch-up program were under-
reported to the register by approximately 15 % [29]; this
would potentially affect the estimated volumes of cy-
tology (including high grade cytology), colposcopies and
precancer treatments. There were some additional limi-
tations of the simple method (which did not apply to the
detailed estimates, and would contribute to the differ-
ences). Firstly, the rescreening behaviour used in the
simple method to estimate the number of women
screened reflect observed behaviour in women in routine
screening (ie those recommended to return at the rou-
tine interval of 2 years for current practice, and 5 years
for HPV-based screening), but were applied to all
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women. This would tend to underestimate the number
of women who are re-screened within a year or two of
their routine screening test, following a screen-detected
abnormality. While this is partially accounted for in the
estimates for HPV-based screening (ie from 2018 on) by
assuming a proportion of women return at 12 months
for follow-up of an initial abnormality, this is likely part
of the reason for the deeper troughs in numbers of
women screened compared to the detailed estimates.
Secondly, the approach of using resource-use rates
which are derived from the cohort model has an implicit
underlying assumption that women have been screened
using the proposed pathway over their screening lives
(for example, that they were predominantly screened
from age 25 and at 5-year intervals). This is likely the
main reason for the greater fluctuation in the simple es-
timates compared to the detailed estimates. The results
from the detailed modelling indicated that resource-use
rates changed over time: the rates eventually approached
the steady-state estimates extracted from the single co-
hort model and used for the simple estimates, but rates
were different during the transition period and for the
first few rounds of five-yearly screening. This was be-
cause in the initial period after transition to a new pro-
gram, most women in the target population for
screening will have commenced screening at a broader
range of ages (from age 18, rather than predominantly at
age 25) and attended more frequently than five-yearly.
Finally, in the simple estimates, the impact of HPV vac-
cination was accounted for by using estimates for co-
horts vaccinated at age 12 in 2009 for all females born
in 1981 or later, who were (or will in future be) offered
HPV vaccination as part of the National HPV Vaccination
Program. This may overestimate vaccine impact in those
vaccinated at older ages, as early analyses of linked vaccin-
ation and screening data in Australia confirm that vaccine
effectiveness varies with age at vaccination [30]. Conversely,
using results from a cohort offered vaccination at age 12 in
2009 will potentially underestimate the impact of vaccin-
ation in younger birth cohorts offered vaccination at age 12
in 2010 or later. The impact of vaccination is expected to
be stronger in these younger birth cohorts, because indirect
effects of vaccination will become stronger as more of the
population is vaccinated, including males. Even considering
only those cohorts vaccinated as 12 year olds (and not
catch-up cohorts), those offered vaccination at age 12 in
2010 or later are likely to experience greater indirect
protection from males being included in the vaccination
program than the cohort modelled here, because they are
more likely in the future to partner with males in cohorts
who have been offered vaccination. The earliest cohort of
boys offered vaccination are slightly younger than the co-
hort of girls offered vaccination at age 12 in 2009, whereas
females are much more likely to mix sexually with similar
age or slightly older males than with younger males
[31, 32]. There may additionally have been some elect-
ive uptake of HPV vaccination among women who were
aged 27 years or older in 2007, however this effect is likely
to be small given the high cost of the vaccine and the po-
tentially lower effectiveness at increasing age of vaccination.
We predict here that there is likely to be an initial
fluctuation (increase) in colposcopies and precancer
treatments after the transition to the renewed primary
HPV-based screening program. This is dependent on
two factors – transitional issues of changing to a longer
interval, but also the improved detection (and thus
higher referral) associated with the introduction of a
more sensitive screening test. This increase will be miti-
gated by vaccine effect, which will particularly limit re-
ferrals in younger women. Therefore it should be noted
that our findings for the extent of the transitional in-
crease are sensitive to the modelled vaccine impact.
However it should be noted that our modelling of vac-
cine impact has been based on the conservative estimate
of three-dose uptake from the national register. As pre-
viously noted reporting to the register is potentially
under-reported for any doses delivered through primary
care, and this would particularly affect the estimates for
women vaccinated as young adults in the catch-up pro-
gram, who will be aged in their late 20s to 30s over the
first round of screening. Some protection may also have
been conferred in females who received fewer than three
doses [33]. There are also a number of other assump-
tions about vaccine efficacy that have potential to impact
our estimates. If we have somewhat underestimated the
extent of vaccine-induced changes by 2017, our esti-
mates for test volumes will be higher than those that will
be eventually observed. Therefore, sentinel data now be-
ing obtained from a major trial, Compass (www.compas-
strial.org.au) will be very important in quantifying
expected test and procedure volumes and referral rates
for the renewed program as a whole. Detailed manage-
ment of screen-detected abnormalities is still to be
underpinned by clinical guidelines (this process is cur-
rently underway and likely to be completed in early-mid
2016). In the absence of these guidelines, the assump-
tions we made were based on advice from an expert ad-
visory committee convened as part of the Renewal
review process [2]. Volumes of some tests may vary if
the final guidelines differ from those assumptions. For
example, volumes are likely to be affected by the post-
colposcopy management of women without histologically-
confirmed high grade, or with discordant results, or who
are positive for non-16/18 oncogenic types, in particular
those with low grade cytology. Volumes are also likely to
be affected by women’s compliance with the recommen-
dation to attend for colposcopy, which in turn could be in-
fluenced by the follow-up protocols and target timeframes
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under the program. The guidelines recommendation that
an exit screening round be undertaken in women attend-
ing for screening when aged 70-74 years (rather than
maintaining the current end age of 69, as was modelled) is
also likely to affect volumes.
Conclusions
Fluctuations in volumes of tests and procedures are pre-
dicted in the first rounds of screening as a result of the
transition from a 2-year to a 5-year recommended interval
in Australia. This is an effect of the switch to a longer inter-
val within a comparatively brief timeframe, and so some de-
gree of fluctuation could be expected in any setting where
this occurs. These fluctuations in volumes are likely to pose
resourcing and workforce challenges which will require
specific planning. These fluctuations are expected to reduce
with each successive screening round. Detailed modelling
of the screening program change gave important insights
into the extent of fluctuations. HPV vaccination is predicted
to counteract increases in high grade cytology results, col-
poscopies and precancer treatments which would otherwise
be anticipated over the next 15 years (regardless of screen-
ing program design) due to population increases.
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